Example: air traffic controller
CELLCEPT Prescribing Information - Genentech
proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. ... · Pediatric Use: Safety and effectiveness in allogenic heart or liver ... suspension for pediatric kidney transplant patients 3 months and older is 600 mg/m2, ...
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION ACTEMRA …
www.gene.com162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response Patients at or above 100 kg weight 162 mg administered subcutaneously every week Giant Cell Arteritis (2.2) Recommended Adult Subcutaneous Dosage: The recommended dose of ACTEMRA for adult patients with GCA is 162 mg
OCREVUS Prescribing Information - Genentech
www.gene.comHepatitis B Virus Screening Prior to initiating OCREVUS, perform Hepatitis B virus (HBV) screening. OCREVUS is contraindicated in patients with active HBV confirmed by positive results for HBsAg and anti-HBVtests. For patients who are negative for surface antigen [HBsAg] and positive for HB core antibody [HBcAb+] or are carriers of HBV
XOLAIR Prescribing Information - Genentech
www.gene.comCorticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of XOLAIR therapy. (5.4) Eosinophilic Conditions: Be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or Fever, Arthralgia, and Rash: Stop XOLAIR if patients develop signs and sickness. (5.6)
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.gene.com1 . HIGHLIGHTS OF PRESCRIBING INFORMATION . These highlights do not include all the information needed to use TAMIFLU safely and effectively. See full prescribing information for
Initial dose of 4 mg/kg over 90 minute IV infusion, …
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION The …
www.gene.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for
Reference ID: 4212951 - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COTELLIC safely and effectively. See full prescribing information …
Valcyte Master USPI - Genentech
www.gene.com1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use VALCYTE ® safely and effectively. See full prescribing information …
HIGHLIGHTS OF PRESCRIBING INFORMATION - Genentech
www.gene.com2 FULL PRESCRIBING INFORMATION WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY Cardiomyopathy Herceptin administration can …
HIGHLIGHTS OF PRESCRIBING INFORMATION The dose for …
www.gene.comfull prescribing information warning: fatal infusion reactions, severe mucocutaneous reactions, hepatitis b virus reactivation and progressive
Related documents
Proton Pump Inhibitors: Use in Pediatric Patients
www.cms.gov2 Proton Pump Inhibitors: Use in Pediatric Patients. FDA-Approved Indications for Proton Pump Inhibitors in Pediatric Patients. Medications in the PPI drug therapy class have been proven safe and effective in children and adolescents for . the short-term treatment of GERD and EE. However, PPIs are often used to treat conditions that have not been
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
www.merck.com8.4 Pediatric Use 8.5 Geriatric Use 8.6 Hepatic Impairment 8.7 Renal Impairment 8.8 Race/Ethnicity 11 DESCRIPTION ... ENTEREG is not recommended for use inthese patients. 6 ADVERSE REACTIONS ... (proton pump inhibitors (PPIs), histamine-2 ...
Perioperative Medication Management - Adult/Pediatric ...
www.uwhealth.orgJul 27, 2020 · 1.2 Proton pump inhibitors: dexlansoprazole, esomeprazole, lansoprazole, omeprazole, omeprazole/sodium bicarbonate, pantoprazole, rabeprazole 1.2.1 Parathyroid surgery 1.2.1.1 Recommend to hold proton pump inhibitors 7 days prior to and day of surgery and post-operatively until directed to resume by surgeon. (UW Health strong
Dose Conversion Chart for PPIs for IV Administration
www.clevelandclinicmeded.comthe Cleveland Clinic Hospitals have made a change in the automatic therapeutic interchange for the proton pump inhibitors (PPIs). As of January 3, 2006, the PPI on the Cleveland Clinic Formulary for adult patients who do not require a suspension is esomeprazole (Nexium®). All new medication orders for PPIs (e.g., lansoprazole, omeprazole ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.talicia.comTALICIA is contraindicated in patients with known hypersensitivity to the components of TALICIA: amoxicillin [or other β-lactam antibacterial drugs (e.g., penicillins and cephalosporins)], omeprazole (or other benzimidazoles [e.g. proton pump inhibitors (PPIs) and anthelmintics]), rifabutin (or any other rifamycins), or
HIGHLIGHTS OF PRESCRIBING INFORMATION ——— …
www.novo-pi.com• For pediatric patients requiring less than 5 units of TRESIBA ® each day, use a TRESIBA U-100 vial (2.1). • In adults, inject subcutaneously once daily at any time of day (2.2). • In pediatric patients inject subcutaneously once daily at the same time every day (2.2). • Individualize dose based on type of diabetes, metabolic
CALQUENCE PRESCRIBING INFORMATION
den8dhaj6zs0e.cloudfront.netTable 1: Recommended Dose Modifications for Use with CYP3A Inhibitors or Inducers CYP3A Co-administered Drug Recommended CALQUENCE use Inhibition Strong CYP3A inhibitor Avoid concomitant use. If these inhibitors will be used short-term (such as anti-infectives for up to seven days), interrupt CALQUENCE. Moderate CYP3A inhibitor 100 mg once daily.